^
    4d
    SELCLAX: Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=42, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2025 --> Jun 2027
    Trial completion date • Combination therapy
    |
    Venclexta (venetoclax) • cytarabine • Xpovio (selinexor) • methotrexate • fludarabine IV • Neupogen (filgrastim)
    5d
    Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, University of Washington
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
    19d
    Split-Dose R-CHOP for Older Adults With DLBCL (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, University of Wisconsin, Madison | Trial completion date: May 2026 --> Feb 2027
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    24d
    Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure (clinicaltrials.gov)
    P2, N=56, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Recruiting --> Active, not recruiting | N=162 --> 56
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • pentostatin • Neupogen (filgrastim)
    1m
    G-CSF After Chemo-radiation in Patients with Glioblastoma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Massachusetts General Hospital | N=40 --> 60
    Enrollment change
    |
    temozolomide • Neupogen (filgrastim)
    1m
    G-CSF After Chemo-radiation in Patients with Glioblastoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Massachusetts General Hospital | N=60 --> 40
    Enrollment change
    |
    temozolomide • Neupogen (filgrastim)
    1m
    Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (clinicaltrials.gov)
    P1, N=0, Withdrawn, M.D. Anderson Cancer Center | N=24 --> 0 | Trial completion date: Dec 2029 --> Nov 2024 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2029 --> Nov 2024
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    paclitaxel • Neupogen (filgrastim)
    2ms
    Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma (clinicaltrials.gov)
    P2, N=65, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • Neupogen (filgrastim) • dexrazoxane
    2ms
    Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma (clinicaltrials.gov)
    P3, N=479, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Dec 2025
    Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • mesna • Neupogen (filgrastim)
    2ms
    Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma (clinicaltrials.gov)
    P3, N=60, Active, not recruiting, Children's Oncology Group | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • thiotepa • Neupogen (filgrastim)
    2ms
    G-CSF After Chemo-radiation in Patients with Glioblastoma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Massachusetts General Hospital
    New P2 trial
    |
    temozolomide • Neupogen (filgrastim)
    2ms
    RAFA: HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (clinicaltrials.gov)
    P2, N=70, Recruiting, Children's Hospital Medical Center, Cincinnati | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • busulfan • Neupogen (filgrastim)
    2ms
    Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation (clinicaltrials.gov)
    P2, N=170, Active, not recruiting, St. Jude Children's Research Hospital | Recruiting --> Active, not recruiting | N=52 --> 170
    Enrollment closed • Enrollment change
    |
    Rituxan (rituximab) • cyclophosphamide • Blincyto (blinatumomab) • sirolimus • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    3ms
    SGN35-027: Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=255, Terminated, Seagen Inc. | Trial completion date: Jun 2026 --> Aug 2024 | Active, not recruiting --> Terminated; The study was prematurely discontinued as the sponsor believes the data collected is enough to show the safety and efficacy of the combinations studied in all cohorts. The decision was not based on any safety and/or efficacy concerns.
    Trial completion date • Trial termination
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    3ms
    Comparison of the efficacy of a generic plerixafor versus Mozobil as adjunct peripheral blood stem cell mobilization agents in multiple myeloma patients. (PubMed, Transfusion)
    The generic plerixafor produced comparable cumulative collection yields and early engraftment outcomes as Mozobil, but fewer doses and collection days were needed to reach collection goal.
    Journal
    |
    CD34 (CD34 molecule)
    |
    Neupogen (filgrastim) • plerixafor
    3ms
    Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF (clinicaltrials.gov)
    P=N/A, N=100, Completed, Cairo University | Recruiting --> Completed | Trial completion date: Nov 2023 --> Sep 2024 | Trial primary completion date: Oct 2023 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Neupogen (filgrastim)
    3ms
    NCI-2018-01607: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    FLT3 positive
    |
    sorafenib • cyclophosphamide • fludarabine IV • busulfan • Neupogen (filgrastim)
    3ms
    Continuous Versus Bolus Administration of G-CSF in Children With Cancer (clinicaltrials.gov)
    P4, N=20, Active, not recruiting, Chang Gung Memorial Hospital | Recruiting --> Active, not recruiting | N=40 --> 20
    Enrollment closed • Enrollment change
    |
    Granocyte (lenograstim) • Neupogen (filgrastim)
    3ms
    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=270, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cytarabine • decitabine • Mylotarg (gemtuzumab ozogamicin) • idarubicin hydrochloride • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    3ms
    Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2; N=31; Not yet recruiting; Sponsor:Medical College of Wisconsin
    New P2 trial
    |
    clonoSEQ
    |
    doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    3ms
    St. Jude ELIOT: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Oct 2024 --> Mar 2025
    Trial completion date • Combination therapy
    |
    gemcitabine • cyclophosphamide • prexasertib (ACR-368) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    4ms
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=68, Recruiting, University of Washington | Suspended --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 translocation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Neupogen (filgrastim)
    4ms
    Haploidentical HCT for Severe Aplastic Anemia (clinicaltrials.gov)
    P2, N=21, Recruiting, St. Jude Children's Research Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • mesna • Neupogen (filgrastim)
    4ms
    Off-the-shelf NK Cells + SCT for Myeloid Malignancies (clinicaltrials.gov)
    P1/2, N=24, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • MECOM (MDS1 And EVI1 Complex Locus) • NUP214 (Nucleoporin 214) • GATA2 (GATA Binding Protein 2) • DEK (DEK Proto-Oncogene)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    4ms
    DEPEND: De-Escalation Therapy for Human Papillomavirus Negative Disease (clinicaltrials.gov)
    P2, N=36, Recruiting, University of Chicago | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    TMB (Tumor Mutational Burden)
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • paclitaxel • 5-fluorouracil • hydroxyurea • Neupogen (filgrastim)
    4ms
    Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=0, Withdrawn, Medical College of Wisconsin | N=36 --> 0 | Initiation date: May 2024 --> Aug 2024 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial initiation date • Trial withdrawal
    |
    Venclexta (venetoclax) • cytarabine • navitoclax (ABT 263) • mitoxantrone • Neupogen (filgrastim)
    4ms
    CRAFT: Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (clinicaltrials.gov)
    P2, N=52, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • Rozlytrek (entrectinib) • cyclophosphamide • etoposide IV • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    5ms
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=68, Suspended, University of Washington | N=50 --> 68
    Enrollment change
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Neupogen (filgrastim)
    5ms
    ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date • Viral vector
    |
    CD34 (CD34 molecule)
    |
    busulfan • Neupogen (filgrastim)
    5ms
    Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation (clinicaltrials.gov)
    P2, N=52, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • cyclophosphamide • Blincyto (blinatumomab) • sirolimus • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    5ms
    Cisplatin-induced bone marrow failure in an adult patient with Fanconi anemia. (PubMed, J Oncol Pharm Pract)
    SCC of the head and neck or gynecologic organs in a young adult without known risk factors should prompt consideration of FA. Cisplatin should be avoided in patients with FA.
    Journal
    |
    FANCI (FA Complementation Group I)
    |
    cisplatin • Promacta (eltrombopag) • Neupogen (filgrastim)
    5ms
    Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    carboplatin • Rozlytrek (entrectinib) • cyclophosphamide • etoposide IV • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    5ms
    Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P1/2, N=4, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 4
    Enrollment closed • Enrollment change
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • Elzonris (tagraxofusp-erzs) • mercaptopurine • mesna • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    5ms
    AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P3; Recruiting --> Active, not recruiting
    Combination therapy • Enrollment closed • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • IKZF1 (IKAROS Family Zinc Finger 1) • CSF1R (Colony stimulating factor 1 receptor)
    |
    TruSight RNA Pan-Cancer Panel
    |
    imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • dexrazoxane
    5ms
    NCI-2018-00906: Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation (clinicaltrials.gov)
    P1/2, N=62, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2024 --> Jul 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Neupogen (filgrastim) • captisol-enabled melphalan
    5ms
    hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (clinicaltrials.gov)
    P2, N=16, Recruiting, Leland Metheny | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    temozolomide • carmustine • Neupogen (filgrastim)
    5ms
    CarMob: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Recruiting, Hackensack Meridian Health | Suspended --> Recruiting
    Enrollment open
    |
    cyclophosphamide • carfilzomib • melphalan • Neupogen (filgrastim) • dexamethasone injection
    5ms
    Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New trial
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Neupogen (filgrastim)
    5ms
    Split-Dose R-CHOP for Older Adults With DLBCL (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, University of Wisconsin, Madison | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    5ms
    AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P3, N=218, Completed, Children's Oncology Group | Active, not recruiting --> Completed
    Trial completion
    |
    cytarabine • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • lestaurtinib (CEP-701) • mercaptopurine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Neupogen (filgrastim) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
    5ms
    Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
    P1, N=150, Completed, Children's Oncology Group | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • busulfan • Neupogen (filgrastim)
    5ms
    Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) (clinicaltrials.gov)
    P3, N=1174, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Sep 2025 --> Mar 2024
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)